GSA Capital Partners LLP Purchases New Stake in Edwards Lifesciences Co. (NYSE:EW)

GSA Capital Partners LLP acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 7,291 shares of the medical research company's stock, valued at approximately $481,000.

A number of other hedge funds have also recently bought and sold shares of the company. O Shaughnessy Asset Management LLC grew its position in shares of Edwards Lifesciences by 27.3% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 36,897 shares of the medical research company's stock worth $3,526,000 after buying an additional 7,918 shares during the period. Lake Street Advisors Group LLC grew its holdings in Edwards Lifesciences by 36.2% during the 1st quarter. Lake Street Advisors Group LLC now owns 3,573 shares of the medical research company's stock worth $341,000 after acquiring an additional 950 shares during the period. Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Edwards Lifesciences by 21,094.6% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 19,711 shares of the medical research company's stock valued at $1,884,000 after acquiring an additional 19,618 shares during the last quarter. Crewe Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $28,000. Finally, Delap Wealth Advisory LLC bought a new position in shares of Edwards Lifesciences in the 1st quarter worth $305,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $70.20 on Wednesday. The stock's fifty day moving average price is $67.59 and its two-hundred day moving average price is $75.91. The firm has a market cap of $41.40 billion, a PE ratio of 10.13, a price-to-earnings-growth ratio of 3.81 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm's revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.59 earnings per share. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 in the last quarter. Company insiders own 1.27% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EW. UBS Group cut their target price on Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research note on Tuesday, September 10th. Citigroup cut their price target on shares of Edwards Lifesciences from $83.00 to $77.00 and set a "buy" rating on the stock in a research report on Tuesday, October 1st. Bank of America cut shares of Edwards Lifesciences from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $105.00 to $75.00 in a report on Thursday, July 25th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 28th. Finally, Canaccord Genuity Group reduced their price target on shares of Edwards Lifesciences from $66.00 to $63.00 and set a "hold" rating on the stock in a research report on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of "Hold" and a consensus target price of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.